Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.23.2
Revenues from Contracts and Significant Customers (Tables)
6 Months Ended
Jun. 30, 2023
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

The table below summarizes the Company’s revenue for the three and six months ending June 30, 2023 and 2022:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended June 30, 

​

Six Months Ended June 30, 

​

    

2023

    

2022

    

2023

    

2022

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

Qbrexza

​

$

8,079

​

$

6,111

​

$

12,173

​

$

13,487

Accutane

​

​

5,579

​

​

5,200

​

​

10,227

​

​

10,107

Amzeeq

​

​

1,374

​

​

1,265

​

​

2,568

​

​

4,731

Targadox

​

​

664

​

​

2,756

​

​

1,457

​

​

5,390

Ximino

​

​

155

​

​

1,035

​

​

766

​

​

2,002

Zilxi

​

​

572

​

​

555

​

​

886

​

​

1,297

Exelderm

​

​

538

​

​

1,313

​

​

1,049

​

​

2,017

Collaboration revenue

​

​

183

​

​

577

​

​

364

​

​

1,154

Revenue – related party

​

 

31

​

 

18

​

 

66

​

 

70

Other revenue

​

​

211

​

​

56

​

​

259

​

 

2,556

Net revenue

​

$

17,386

​

$

18,886

​

$

29,815

​

$

42,811